SCHEMBL1845768

SCHEMBL1845768

Oc1ccc(CCc2ccco2)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TYR P14679 6/20 0.62
HTR2B P41595 1/20 0.46
ALOX5 P09917 2/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
HTT P42858 2/20 0.45
KMT2A Q03164 2/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30576428 1.00 TYR (0.62) TYRHTR2BALOX5MEN1MAPT
SCHEMBL30576429 0.84 ALOX5 (0.53) TYRALOX5MEN1MAPTHTT
SCHEMBL1846967 0.84 ALOX5 (0.53) TYRALOX5MEN1MAPTHTT
SCHEMBL21154074 0.80 HTR2B (0.49) HTR2BMEN1KMT2ACYP3A4ALOX15
SCHEMBL1397158 0.79 TYR (1.00) TYRALOX5MEN1MAPTHTT
SCHEMBL8146532 0.74 ALDH1A1 (0.54) HTR2BALOX5MEN1MAPTKMT2A
SCHEMBL29975956 0.74 LMNA (0.41) HTR2BALOX5MEN1MAPTHTT
SCHEMBL6732302 0.74 LMNA (0.41) HTR2BALOX5MEN1MAPTHTT
SCHEMBL24201406 0.74 TYR (0.78) TYRALOX5MEN1MAPTHTT
SCHEMBL2902317 0.71 TYR (0.74) TYRALOX5MEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4046619-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS Unigen, Inc. (US) 2022-08-24 EP claimed
US-8658838-B2 Series of skin whitening (lightening) compounds UNIGEN, INC. (US) 2014-02-25 US claimed
US-20130209383-A1 SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS UNIGEN, INC. (US) 2013-08-15 US claimed
US-8362305-B2 Series of skin whitening (lightening) compounds UNIGEN, INC. (US) 2013-01-29 US claimed
EP-2323612-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS Unigen, Inc. (US) 2011-05-25 EP claimed
WO-2010011630-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS UNIGEN PHARMACEUTICALS, INC. (US) 2010-01-28 WO claimed
US-20100016347-A1 SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS UNIGEN PHARMACEUTICALS, INC. (US) 2010-01-21 US claimed
US-12227472-B2 Series of skin-whitening (lightening) compounds UNIGEN, INC. (US) 2025-02-18 US disclosed
US-20230399282-A1 Series of Skin-Whitening (Lightening) Compounds UNIGEN, INC. (US) 2023-12-14 US disclosed
US-20230399282-A1 Series of Skin-Whitening (Lightening) Compounds UNIGEN, INC. (US) 2023-12-14 US disclosed
US-20230399282-A1 Series of Skin-Whitening (Lightening) Compounds UNIGEN, INC. (US) 2023-12-14 US disclosed
US-11739040-B2 Series of skin-whitening (lightening) compounds UNIGEN, INC. (US) 2023-08-29 US disclosed
US-11739040-B2 Series of skin-whitening (lightening) compounds UNIGEN, INC. (US) 2023-08-29 US disclosed
US-8362305-B2 Series of skin whitening (lightening) compounds UNIGEN, INC. (US) 2013-01-29 US disclosed
US-8362305-B2 Series of skin whitening (lightening) compounds UNIGEN, INC. (US) 2013-01-29 US disclosed
EP-2323612-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS Unigen, Inc. (US) 2011-05-25 EP disclosed
WO-2010011630-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS UNIGEN PHARMACEUTICALS, INC. (US) 2010-01-28 WO disclosed
WO-2010011630-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS UNIGEN PHARMACEUTICALS, INC. (US) 2010-01-28 WO disclosed
US-20100016347-A1 SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS UNIGEN PHARMACEUTICALS, INC. (US) 2010-01-21 US disclosed
US-20100016347-A1 SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS UNIGEN PHARMACEUTICALS, INC. (US) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739040-B2 Series of skin-whitening (lightening) compounds TYR, TH, MAOB TYR 1/4885HTR2B 368/4885ALOX5 301/4885
US-20230399282-A1 Series of Skin-Whitening (Lightening) Compounds TYR, TH, MAOB TYR 1/4885HTR2B 368/4885ALOX5 301/4885
US-20130209383-A1 SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS TYR, MAOB, TH TYR 1/4885HTR2B 410/4885ALOX5 287/4885
US-20100016347-A1 SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS TYR, MAOB, TH TYR 1/4885HTR2B 410/4885ALOX5 287/4885
US-12227472-B2 Series of skin-whitening (lightening) compounds TYR, TH, MAOB TYR 1/4885HTR2B 368/4885ALOX5 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.